Adrenoleukodystrophy Market

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder that is caused by the abnormality in the ABCD1 gene present on the X chromosome, leading to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. 

Adrenoleukodystrophy Epidemiological Segmentation 

The Epidemiological Segmentation of Adrenoleukodystrophy in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent Population of Adrenoleukodystrophy
  • Gender-specific Prevalence of Adrenoleukodystrophy
  • Gender-specific Diagnosed Prevalent Population of Adrenoleukodystrophy
  • Type-specific Diagnosed Prevalence in males of Adrenoleukodystrophy

Adrenoleukodystrophy Epidemiology 

  • The total prevalent population of Adrenoleukodystrophy in the 7MM in 2017 was 55,242
  • The prevalent population of Adrenoleukodystrophy in the United States in 2017 was 19,371 
  • Among the EU5, Germany had the highest diagnosed prevalent population of Adrenoleukodystrophy was 1,699 

Adrenoleukodystrophy Market

Adrenoleukodystrophy Market Size in the United States in 2017 was USD 523.26 million

Adrenoleukodystrophy Market Drivers 

  • Increased number of potential therapies in the pipeline
  • Awareness about newborn screening programs
  • The rise in the number of Childhood Cerebral Adrenoleukodystrophy (CALD) cases

Adrenoleukodystrophy Emerging Drugs

Adrenoleukodystrophy Emerging Drugs are Lenti D, Leriglitazone, MD1003, MGTA-456, OP-101, SOM1201, and many others.  

´╗┐Adrenoleukodystrophy Key Players

Adrenoleukodystrophy key players are bluebird bio, Minoryx Therapeutics, S.L., MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others.